Cargando…
Neuropsychiatric Effects in Patients With Invasive Prolactinomas Treated With Cabergoline
Background and objective Invasive prolactinoma accounts for 1-5% of all prolactinomas. Its mass and compromise of the diencephalon and frontal and temporal lobes may result in a range of neuropsychiatric symptoms that are often missed during initial evaluations. Cabergoline is a dopaminergic agonist...
Autores principales: | Calva-González, Metztli, Villanueva-Solórzano, Pedro Leonardo, Crail-Meléndez, Edgar D, Loya-Murguia, Kennya M, Dehesa Hernandez, Itzel Ariadna, Robles-Ramirez, Fernando, Rodríguez-Hernández, Luis A, Mondragón-Soto, Michel G, Flores-Vázquez, José Guillermo, Portocarrero-Ortiz, Lesly A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315068/ https://www.ncbi.nlm.nih.gov/pubmed/37404423 http://dx.doi.org/10.7759/cureus.39869 |
Ejemplares similares
-
Immunohistochemical Expression of Ki-67, Dopamine D1 and Dopamine D2 Receptors in Meningiomas in a Tertiary Institution in Mexico
por: Rodríguez-Hernández, Luis A, et al.
Publicado: (2023) -
Cabergoline Treatment in Invasive Giant Prolactinoma
por: Alsubaie, Sadeem, et al.
Publicado: (2014) -
Spontaneous reduction of prolactinoma post cabergoline withdrawal
por: Venkatesh, Sampath Kumar, et al.
Publicado: (2012) -
Pituitary Apoplexy during Treatment of Prolactinoma with Cabergoline
por: Ghadirian, Hesam, et al.
Publicado: (2018) -
Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
por: Pala, Nazir A., et al.
Publicado: (2015)